Elsie Biotechnologies

9:30 AM - 9:45 AM (EST), Tuesday, February 7, 2023 ・ Winter Garden
Elsie Biotechnologies is a private, emerging biopharmaceutical company with the mission to unlock the full potential of RNA therapeutics, finally realizing the value to drugging undruggable targets. Our first efforts are to develop best-in-class gene silencing drugs, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA). We are leveraging our platform to optimize current approaches to gene silencing and develop more selective drugs chemically synthesized to be more potent, safer, and easier to deliver to target tissue. This proprietary platform is the first of its kind, designed to integrate the discovery, development, and delivery of nucleic acids as therapies. We envision this platform growing to include any oligonucleotide therapeutic modality, including messenger RNA (mRNA) and single guide RNA (sgRNA).
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2021
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
oligonucleotides in cancer and amyloid diseases
Development Phase of Primary Product:
Discovery
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Elsie Biotechnologies